[CELG] Celgene Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 78.56 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 118.93 Change: 1.06 (0.9%)
Ext. hours: Change: 0 (0%)

chart CELG

Refresh chart

Strongest Trends Summary For CELG

CELG is in the medium-term up 10% in 4 months. In the long-term up 1200% in 27 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company?s commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The company?s

Fundamental Ratios
Shares Outstanding774.6 M EPS3.09 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 14.91% Sales Growth - Q/Q9.47% P/E39.6
P/E To EPS Growth P/S9.32 P/BV12.43 Price/Cash Per Share10.49
Price/Free Cash Flow29.58 ROA12.38% ROE34.76% ROI15.22%
Current Ratio3.34 Quick Ratio3.2 Long Term Debt/Equity0.9 Debt Ratio0.47
Gross Margin95.19% Operating Margin31.72% Net Profit Margin26.08% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-951.3 M Cash From Investing Activities239.7 M Cash From Operating Activities1.14 B Gross Profit2.18 B
Net Profit356.2 M Operating Profit412.4 M Total Assets17.75 B Total Current Assets9.88 B
Total Current Liabilities2.96 B Total Debt7.62 B Total Liabilities11.42 B Total Revenue2.28 B
Technical Data
High 52 week100.95 Low 52 week59.21 Last close100.95 Last change0.56%
RSI64.77 Average true range1.09 Beta1.07 Volume2.51 M
Simple moving average 20 days1.69% Simple moving average 50 days3.66% Simple moving average 200 days8.8%
Performance Data
Performance Week2.09% Performance Month2.61% Performance Quart11.09% Performance Half6.77%
Performance Year22.25% Performance Year-to-date57.51% Volatility daily0.65% Volatility weekly1.44%
Volatility monthly2.96% Volatility yearly10.25% Relative Volume218.43% Average Volume3.53 M
New High New Low

News

2019-11-19 11:16:00 | Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500

2019-11-19 10:30:04 | ‘Hipster Antitrust’ Might End the Megamerger Party

2019-11-19 04:36:00 | [video]ServiceNow Jumps as Stock Is Added to the S&P 500, Replacing Celgene

2019-11-18 17:58:00 | ServiceNow stock up 4% on news it is joining the S&P 500

2019-11-18 17:25:10 | Celgene's Revlimid-Rituximab Combo Gets Positive CHMP Opinion

2019-11-18 17:10:00 | Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019

2019-11-18 09:55:00 | Bristol-Myers Expects to Complete Its Deal for Celgene on Wednesday

2019-11-18 09:18:02 | Bristol-Myers Gets FTC Clearance for Celgene Acquisition

2019-11-18 08:50:01 | Top Ranked Growth Stocks to Buy for November 18th

2019-11-16 10:23:21 | 5 Very Large Cap Stocks Hedge Funds Are Piling Into

2019-11-15 17:43:00 | FTC makes Celgene's Otezla divestiture official condition for Bristol-Myers acquisition

2019-11-15 17:28:20 | Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close Wednesday

2019-11-15 17:18:42 | UPDATE 2-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

2019-11-15 17:00:11 | Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

2019-11-15 12:29:16 | Q3 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios

2019-11-15 07:30:00 | Celgene Receives CHMP Positive Opinion for REVLIMID® lenalidomide in Combination With Rituximab for the Treatment of Adult Patients With Previously Treated Follicular Lymphoma

2019-11-15 02:00:20 | US regulator issues first approval for a Chinese cancer treatment

2019-11-14 10:36:03 | Top Ranked Growth Stocks to Buy for November 14th

2019-11-13 15:43:08 | Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates

2019-11-13 10:00:03 | Editas EDIT Beats on Q3 Earnings, Amends Celgene Deal

2019-11-12 09:14:02 | Top Ranked Growth Stocks to Buy for November 12th

2019-11-12 09:00:00 | Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing

2019-11-12 08:18:01 | The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene

2019-11-11 09:28:02 | 4 Biotech Stocks That Could Keep Beating Wall Street

2019-11-11 09:15:02 | Celgene CELG Hits 52-Week High, Can the Run Continue?

2019-11-11 09:05:02 | Celgene & Acceleron Get FDA Nod for Rare Blood Disorder Drug

2019-11-08 16:25:49 | How Celgene Added A New Drug To Its Wheelhouse A Month Early

2019-11-08 14:24:00 | Celgene's rare disease drug gets FDA approval

2019-11-08 14:20:35 | FDA approves Acceleron's blood disorder drug ahead of schedule

2019-11-08 12:55:14 | UPDATE 2-Celgene's drug for anemia in beta thalassemia priced at $3,441/ 25 mg vial

2019-11-08 12:33:00 | FDA Approves REBLOZYL® luspatercept-aamt for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions

2019-11-08 10:31:03 | Corcept CORT Earnings Beat in Q3, Korlym Boosts Sales

2019-11-07 13:06:10 | P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's confirms Bristol-Myers Squibb at A2; negative outlook

2019-11-06 15:14:08 | Prothena PRTA Reports Narrower-than-Expected Loss in Q3

2019-11-06 11:29:04 | Top Ranked Momentum Stocks to Buy for November 6th

2019-11-06 10:20:03 | Will Celgene CELG Gain on Rising Earnings Estimates?

2019-11-06 10:00:03 | Celgene CELG Is Up 3.16% in One Week: What You Should Know

2019-11-06 09:30:02 | CELG vs. TECH: Which Stock Is the Better Value Option?

2019-11-06 09:30:02 | Is Celgene CELG Outperforming Other Medical Stocks This Year?

2019-11-06 09:06:00 | Celgene to Present New and Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology ASH 2019 Annual Meeting

2019-11-06 08:45:01 | 3 Reasons Why Celgene CELG Is a Great Growth Stock

2019-11-05 13:56:53 | The Biggest Biotech Just Touched A Record High — Is Amgen Stock A Buy?

2019-11-05 10:15:03 | The Zacks Analyst Blog Highlights: Facebook, JPMorgan Chase, Royal Dutch Shell, Starbucks and Celgene

2019-11-05 08:32:01 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-11-04 17:05:10 | Biotech ETFs in Focus on Impressive Q3 Earnings Results

2019-11-04 15:05:08 | Top Stock Reports for Facebook, JPMorgan & Royal Dutch Shell

2019-11-04 13:00:06 | Value Biotech ETFs & Stocks to Buy Now

2019-11-04 11:54:04 | ImmunoGen IMGN Q3 Earnings & Sales Beat, Shares Rally

2019-11-01 12:07:04 | Agios' AGIO Q3 Loss Narrower Than Expected, Revenues Miss

2019-11-01 11:33:54 | 2 Health Stocks With Gains Thursday